At CSL, we're driven by a profound dedication to advancing healthcare and improving patients' lives. As we count down to Rare Disease Day, we're shining a spotlight on a lesser-known but debilitating condition: IgA Nephropathy. IgA Nephropathy, also known as Berger Disease, is a rare autoimmune disorder characterized by an excess of immunoglobulin A \(IgA\) deposits in the kidneys, leading to inflammation and potential long-term kidney damage. IgA Nephropathy is the most common type of primary glomerular disease worldwide and a leading cause of kidney failure. There's no cure for IgA nephropathy, but treatment can slow how quickly it becomes worse and delay kidney failure. This is the reality for countless individuals living with IgA nephropathy, as they navigate through treatments and strive for a better quality of life. At CSL, we're not just aware of these challenges; we're actively working to address them as we continue to deliver on our promise to patients. Stay tuned as we share updates on our progress and initiatives in IgA Nephropathy. Learn more about our focus on nephrology https://bit.ly/3wvZnaq #IgANephropathy #RareDisease #RareDiseaseDay #PatientCare
Vita: Original Stories
'Vita' means life. It's also where we share the stories of biotech's promise to patients and public health.
2024 Black Pearl Awards
EURORDIS, which represents rare disease patients in Europe, celebrates advocates who distinguish themselves in categories inc…
Supporting Progress With the Urban League
Since 1910, the national organization has been creating opportunities for underserved communities. This month, the President …
Careers at CSL
We are committed to helping employees fulfill their career aspirations while working in a values-based culture. Are you next?